Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2023 | The importance of the MDT to provide adequate treatment and care to patients with amyloidosis

Paolo Milani • 8 Jun 2023
EHA 2023
Amyloidosis Rare Diseases

Paolo Milani, MD, PhD, Amyloidosis Research and Treatment Center, Pavia, Italy, emphasizes the importance of using a multidisciplinary team (MDT) in the care of patients with AL amyloidosis. Dr Milani explains that specialists including cardiologists, nephrologists, and neurologists are essential to provide adequate treatment and supportive care. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Paolo Milani

3:14
The impact of amyloid deposits in AL amyloidosis
Paolo Milani • 22 Nov 2023
4:27
The unmet needs in AL amyloidosis and limitations of the current SoC
Paolo Milani • 22 Nov 2023
4:01
Dara-based regimens vs CyBorD in patients with AL amyloidosis & stage IIIb cardiac involvement
Paolo Milani • 22 Nov 2023
1:08
The clinical features of pulmonary light chain amyloidosis
Paolo Milani • 8 Jun 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals